Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial

BJU International

Volumn 112, Issue 6, 2013, Pages 735-741

  Yli Hemminki, Tytti H ^a,b   Laurila, Marita ^a   Auvinen, Anssi ^c   Määttänen, Liisa ^d   Huhtala, Heini ^c   Tammela, Teuvo L J ^a   Kujala, Paula M ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

Author keywords

inflammation; mass screening; needle biopsy; prostatic neoplasms; prostatitis; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FINLAND; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

INFLAMMATION; MASS SCREENING; NEEDLE BIOPSY; PROSTATIC NEOPLASMS; PROSTATITIS; PSA;

AGED; BIOPSY; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884286840     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12153     Document Type: Article

References (33)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E,. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916
2. Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846-851
3. Mistry K, Cable G,. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003; 16: 95-101
4. van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH,. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95: 1462-1466
5. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM,. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335-342
6. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 2005; 294: 66-70
7. Auvinen A, Raitanen J, Moss S, et al. Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands. Cancer Epidemiol Biomarkers Prev 2009; 18: 2000-2005
8. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328
9. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543
10. Hasui Y, Marutsuka K, Asada Y, Ide H, Nishi S, Osada Y,. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 1994; 25: 91-96
11. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL,. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407-413
12. Okada K, Kojima M, Naya Y, et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000; 55: 892-898
13. Wolters T, Roobol MJ, Schröder FH, et al. Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years? BJU Int 2008; 101: 283-288
14. Karakiewicz PI, Benayoun S, Bégin LR, et al. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract 2007; 61: 425-430
15. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269
16. Mahmud S, Franco E, Aprikian A,. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90: 93-99
17. Mahmud SM, Franco EL, Turner D, et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 2011; 6: e16412
18. Jacobs EJ, Newton CC, Stevens VL, Gapstur SM,. A large cohort study of long-term acetaminophen use and prostate cancer incidence. Cancer Epidemiol Biomarkers Prev 2011; 20: 1322-1328
19. De Marzo AM, Marchi VL, Epstein JI, Nelson WG,. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-1992
20. Woenckhaus J, Fenic I,. Proliferative inflammatory atrophy: a background lesion of prostate cancer? Andrologia 2008; 40: 134-137
21. Määttänen L, Auvinen A, Stenman UH, et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79: 1210-1214
22. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID,. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001; 87: 797-805
23. Molimard B, Camparo P, Desfemmes FR, et al. Predictive value of the asymptomatic prostatic inflammation in the development of prostate cancer. Prog Urol 2010; 20: 508-514
24. MacLennan GT, Eisenberg R, Fleshman RL, et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006; 176: 1012-1016
25. Delongchamps NB, de la Roza G, Chandan V, et al. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736-1740
26. Van Hemelrijck M, Jungner I, Walldius G, et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer 2011; 129: 1485-1492
27. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-1547
28. Bernoulli J, Yatkin E, Laakso A, et al. Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. Prostate 2008; 68: 728-739
29. Dennis LK, Lynch CF, Torner JC,. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78-83
30. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ,. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status among Men. Urology 1998; 51: 578-584
31. Kilpeläinen TP, Tammela TL, Määttänen L, et al. False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer 2010; 102: 469-474
32. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246
33. Sfanos KS, De Marzo AM,. Prostate cancer and inflammation: the evidence [Review]. Histopathology 2012; 60: 199-215